STEP 1 (double-blind)
- Population
- 1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes
- Comparison
- Semaglutide 2.4 mg vs placebo, plus lifestyle intervention
- Comparator
- Placebo plus lifestyle intervention (2:1 randomization)
- Endpoint
- Percent change in body weight and weight reduction of at least 5% (coprimary)
- Time point
- 68 weeks
- Result
- -14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points
- Uncertainty
- Difference 95% CI -13.4 to -11.5
- Source
- PMID 33567185, doi:10.1056/NEJMoa2032183, registry NCT03548935
- Where each number sits (matched)
- Flagship Weight Management 1.3.0: open "Verify this result" on the result for the table, figure or text location of each displayed number.
Limits of this record
- Treatment-policy primary estimand: effects regardless of adherence and of other anti-obesity treatment or rescue (the publication abstract's wording is "regardless of treatment discontinuation or rescue interventions"). The displayed difference of -12.4 points (95% CI -13.4 to -11.5) matches the registry's ANCOVA treatment difference, the method the plan specifies for this estimand. The arm values -14.9% and -2.4% are verified in the abstract only; the registry posts different, observed means.
Open “Verify this result” for locators, automated checks and the list of what is unverified.